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Mammalian target of rapamycin (mTOR), a large multi-
domain protein kinase, regulates cell growth and metab-
olism in response to environmental signals. The FKBP
rapamycin-binding (FRB) domain of mTOR is a validated
therapeutic target for the development of immunosup-
pressant and anticancer drugs but is labile and insoluble.
Here we designed a fusion protein between FKBP12 and
the FRB domain of mTOR. The fusion protein was suc-
cessfully expressed in Escherichia coli as a soluble form,
and was puriﬁed by a simple two-step chromatographic
procedure. The fusion protein exhibited increased solubi-
lity and stability compared with the isolated FRB domain,
and facilitated the analysis of rapamycin and FK506
binding using differential scanning calorimetry (DSC)
and solution nuclear magnetic resonance (NMR). DSC
enabled the rapid observation of protein–drug inter-
actions at the domain level, while NMR gave insights into
the protein–drug interactions at the residue level. The
use of the FKBP12–FRB fusion protein combined with
DSC and NMR provides a useful tool for the efﬁcient
screening of FKBP12-dependent as well as -independent
inhibitors of the mTOR FRB domain.
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Introduction
Microcalorimetry and nuclear magnetic resonance (NMR)
are useful tools for the assessment of protein–ligand
interactions (Bewlley et al., 2004; Crump et al., 2004).
Isothermal titration calorimetry is often used for the direct
measurement of thermodynamic parameters of protein–
ligand interactions, while differential scanning calorimetry
(DSC) provides information on protein unfolding. Ligand
association is generally accompanied by an increase in the
transition temperature (TM) of unfolding so that DSC could
provide a convenient tool for detecting protein–ligand inter-
actions (Waldron and Murphy, 2003). NMR, on the other
hand, provides information on protein–ligand interactions at
the residue level. A combination of DSC and NMR enables
the rapid and detailed assessment of protein–ligand inter-
actions and can help in the search for and design of drug
candidates.
FK506 (Kino et al., 1987a,b) and rapamycin (Vezina
et al., 1975; Sehgal et al., 1987) associate with the same cel-
lular target, the 12-kDa FK506-binding protein (FKBP12), a
peptidylprolyl cis/trans isomerase (PPIase). FK506 (Fig. 1a)
was ﬁrst isolated from Streptomyces tsukubaensis in
Tsukuba, and rapamycin (Fig. 1b) from Streptomyces hygro-
scopicus in Easter Island. Both of these reagents have been
used clinically as immunosuppressants in transplant patients.
However, their pharmacological mechanisms after associ-
ation with FKBP12 show signiﬁcant differences. The
FK506–FKBP12 complex acts as an inhibitor of calcineurin,
an intracellular Ca
2þ-dependent phosphatase (Liu et al.,
1991; Schreiber, 1992). In contrast, the rapamycin–FKBP12
complex associates with the FKBP rapamycin binding (FRB)
of mammalian target of rapamycin (mTOR) to inhibit the
biological activity of mTOR (Huang et al., 2003).
mTOR is a large protein kinase (2549 residues) that con-
tains a number of distinct functional domains from the N- to
C-terminus, including 12 HEAT (1–1480) repeats, an FAT
domain (1513–1910), an FRB domain (2015–2114), a cata-
lytic domain (2181–2484) and an FATC domain (2517–
2549). mTOR was found in two functionally and structurally
distinct multiprotein complexes, mTORC1 and mTORC2.
The rapamycin-sensitive complex, mTORC1, transmits nutri-
ent availability signals to control numerous cellular functions
(Heitman et al., 1991; Schmelzle and Hall, 2000;
Wullschleger et al., 2006), whereas the rapamycin-insensitive
complex, mTORC2, regulates actin cytoskeleton assembly
and activates a protein kinase, AKT (Jacinto et al., 2003;
Sarbassov et al., 2004, 2005). Thus, mTOR plays a key role
in the regulation of cell growth and survival, and is a critical
target for cancer therapy (Chan, 2004; Rosner et al., 2008).
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ligand-free state was reported (Dames, 2008), and its inter-
actions with new potential inhibitors have been characterized
by solution NMR (Leone et al., 2006; Veverka et al., 2008).
In these reports, the FRB domain was expressed as an
inclusion body in Escherichia coli, solubilized using a chao-
tropic reagent, refolded to the native state and then further
puriﬁed by chromatography. However, the solubility and
stability of the FRB domain were quite low at ambient temp-
erature. Hence, a highly soluble and stable FRB construct is
required to screen inhibitors of the mTOR FRB domain.
Here we prepared a fusion protein between FKBP12 and
mTOR FRB (Fig. 2a). The fusion protein was successfully
expressed as a soluble form in E.coli and could be puriﬁed
by simple two-step chromatography. We characterized the
interactions of the fusion protein with FK506 and rapamycin,
and demonstrated that DSC enables the rapid observation of
the protein–drug interactions at the domain level, while
NMR gives insights on the protein–drug interactions at the
residue level. The use of the fusion protein of FKBP12 and
the mTOR FRB domain combined with DSC and NMR
methods provides a useful tool for the efﬁcient screening of
FKBP12-dependent as well as -independent inhibitors of the
mTOR FRB domain.
Materials and method
Construction of the expression plasmid
The FKBP12 expression vector was constructed as follows.
The coding sequence of human FKBP12 was ampliﬁed using
the nucleotides FKBP12-f (50-CCTCTAGACATATGATGGG
AGTGCAGGTGGAAACC-30) and FKBP12-r (50-AGACTC
GAGATTATCATTCCAGTTTTAGAAGCTCC-30), digested
using NdeI and XhoI, and cloned into pGBHPS (Kobashigawa
et al., 2009) using the same sites.
The expression plasmid for the mTOR FRB domain was
constructed as follows. The fragment encoding the human
mTOR FRB (2015–2114) domain was ampliﬁed using the
oligonucleotides FRB-f (50-CCTCTAGACATATGGAGCTG
ATCCGAGTGGCCATC-30) and FRB-r (50-AGACTCGAGA
TTACTGCTTTGAGATTCGTCGGAAC-30), digested using
NdeI and XhoI, and cloned into pGBHPS (Kobashigawa
et al., 2009) using the same sites.
The expression plasmid for FKBP12–FRB was con-
structed as follows. The fragment encoding the human
mTOR FRB (2015–2114) domain was ampliﬁed using the
oligonucleotides FRB-f2 (50-CGGGGTACCGAGCTGATCC
GAGTGGCC-30) and FRB-r2 (50-AGACTCGAGATTACTG
CTTTGAGATTCGTCGGAAC-30), and digested using KpnI
and XhoI. The fragment encoding human FKBP12 was
ampliﬁed using the oligonucleotides FKBP12-f and FKBP12-r2
(50-AGAGGATCCTTCCAGTTTTAGAAGCTCC-30), and
digested using NdeI and BamHI. The linker was constructed
as GSGSSGSSGSSGT, ampliﬁed using the oligonucleotides
(50-GATCCGGCAGCTCGGGTAGTAGCGGGAGCTCCGG
TAC-30) and (50-CGGAGCTCCCGCTACTACCCGAGCTGC
CG-30), and the product was digested using BamHI and
KpnI. The three polymerase chain reaction (PCR) products
were then linked using ligation high V.2 (TOYOBO). After
Fig. 1. Chemical structures of FK506 (a) and Rapamycin (b).
Fig. 2. (a) Schematic representation of the construction of the
FKBP12-mTOR FRB fusion protein. (b) SDS-PAGE analysis for
puriﬁcation of the FKBP12–FRB fusion protein. Lane 1: after Ni-NTA
puriﬁcation, lane 2: after HRV 3C protease digestion lane 3: after
puriﬁcation by gel ﬁltration chromatography.
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812puriﬁcation, the ligation product was ampliﬁed by PCR using
the oligonucleotides FKBP12-f and FRB-r2, digested using
NdeI and XhoI and cloned into pGBHPS (Kobashigawa
et al., 2009) using the same sites.
The FKBP38 expression vector was constructed as follows.
The fragment encoding the human FKBP38 PPI domain (92–
210) domain was ampliﬁed using the oligonucleotides
FKBP38-f (50-CCTCTAGACATATGGAGTGGCTGGACATTC-30)
and FKBP38-r (50-AGACTCGAGATTACTCCAGGTCAGG
CCCGTCC-30), digested using NdeI and XhoI and cloned into
pGBHPS (Kobashigawa et al., 2009) using the same sites.
The expression plasmid for FKBP38–FRB was constructed
as follows. The fragment encoding the human mTOR FRB
(2015–2114) domain ampliﬁed as previously mentioned. The
fragment encoding human FKBP38 (92–210) was ampliﬁed
using the oligonucleotides FKBP38-f and FKBP38-r2
(50-GGACGGGCCTGACCTGGAGGGATCCTCT-30), and
digested using NdeI and BamHI. The linker was constructed
as GSGSSGSSGSSGT, as same as FKBP12–FRB. The three
PCR products were then linked using ligation high V.2
(TOYOBO). After puriﬁcation, the ligation product was
ampliﬁed by PCR using the oligonucleotides FKBP38-f and
FRB-r2, digested using NdeI and XhoI and cloned into
pGBHPS (Kobashigawa et al., 2009) using the same sites.
Protein expression and puriﬁcation
FKBP12, FKBP38 PPI domain and the FKBP12–FRB,
FKBP38–FRB fusion protein were expressed in E.coli at 258C
as GB1-fusion proteins. The GB1, hexahistidine tags and the
HRV3C protease cleavage site was fused to the N-terminus of
FKBP12. For DSC measurements, the proteins were expressed
in E.coli in 2 YT medium. For NMR, the proteins were isoto-
pically
13C- and
15N-labeled by growing E.coli Rossetta2 (DE3)
in M9 minimal medium containing
15NH4Cl,
13C-glucose and
Celtone-CN (Spectral Stable Isotopes) as the sole nitrogen and
carbon sources. Protein expression was induced by the addition
of isopropyl-1-thio-b-galactpyranoside to a ﬁnal concentration
of 1 mM at 168C. The cells were then cultured overnight at
168C. The GB1- and hexahistidine-tagged FKBP12–FRB and
FKBP38–FRB fusion protein were puriﬁed using Ni-NTA resin
(Quiagen), and the GB1 and hexahistidine tags were removed
by HRV3C protease. The samples were further puriﬁed using a
Superdex 75 gel ﬁltration column (GE Healthcare). The total
yields of FKBP12, FKBP38 PPI domain and the FKBP12–
FRB, FKBP38–FRB fusion protein were 40, 25, 24 and 17 mg/
l, respectively.
DSC measurements
Calorimetric measurements were carried out with a VP-DSC
microcalorimeter (MicroCal) at a scanning rate of 18C/min
from 293 to 353 K. All scans were obtained at a protein con-
centration of 0.1 mM for both FKBP12 and FKBP38 PPI
domain, and the FKBP12–FRB and FKBP38–FRB fusion
protein. Ligand concentrations were 1 mM for both rapamy-
cin and FK506. All scans were acquired in 20 mM Tris-HCl
(pH 8.0) and 150 mM NaCl. All the DSC data were analyzed
using Origin 7.0 software (MicroCal).
NMR spectroscopy
FKBP12 and FKBP38 PPI domain, and the FKBP12–FRB
and FKBP38–FRB fusion proteins were dissolved in 20 mM
NaPi buffer (pH 7.2) or 20 mM Tris-HCl and 150 mM NaCl
(pH 8). Rapamycin or FK506 (100 mM in DMSO-d6) were
added to 250 ml of protein-containing sample. All NMR
spectra were obtained on Varian Unity INOVA 600 or 800
spectrometers at a temperature of 258C. The data were pro-
cessed using VnmrJ 2.2D and Olivia (http://fermi.pharm.
hokudai.ac.jp/). Backbone resonance assignments were
obtained using a standard set of triple-resonance experiments.
Results and discussion
Design, expression and puriﬁcation of the fusion protein
between FKBP and FRB
The isolated FRB domain was neither soluble nor stable
enough for NMR analysis at 258C. The NMR sample was
precipitated, and the signal intensity was reduced within
several hours (data not shown). A highly soluble and stable
protein tag (e.g. GB1, thioredoxin and MBP) is generally
attached to the target protein to improve solubility and stab-
ility. Here, instead of attaching a general solubilizing tag, we
used a highly stable and soluble protein, FKBP12, as a
fusion tag of the FRB domain (Fig. 2a). This also facilitates
the screening of FKBP12-dependent mTOR FRB inhibitors.
According to the crystal structure of the FKBP12–rapamy-
cin–FRB ternary complex (Choi et al., 1996; Liang et al.,
1999), the C-terminus of FKBP12 is located near the
N-terminus of the FRB domain, indicating that the termini
could be connected by a covalent linker. The N-terminus of
the FRB domain (E2014 to W2023) is ﬂexible in the crystal
structure. Considering that the distance from FKBP12 E107
to FRB H2024 is 28 A ˚, a minimum of seven additional
amino acid residues would be required for spanning this dis-
tance. Thus, the FKBP12–FRB fusion protein with a linker
of 13 amino acid residues in length was designed.
The FKBP12–FRB fusion protein was expressed in E coli
with the GB1 and hexahistidine tags attached to the
N-terminus (Kobashigawa et al., 2009). The supernatant was
Fig. 3. Heat capacity curves of FKBP12 and the FKBP12–FRB fusion
protein obtained by DSC. (a) The DSC curves of FKBP12. (b) The DSC
curves of the FKBP12–FRB fusion protein under three different conditions:
without ligand binding (black), in the presence of FK506 (blue) and in the
presence of rapamycin (red).
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813puriﬁed using Ni-NTA resin (Quiagen), and the tags were
removed by HRV3C protease digestion. The fusion protein
was further puriﬁed by gel ﬁltration using Superdex 75 (GE
Healthcare) to a single band in sodium dodecyl sulfate
polyacrylamide gel electrophoresis analysis (Fig. 2b). The
total yield of the FKBP12–FRB fusion protein was 34 mg/l,
which was sufﬁcient for the subsequent biophysical
analyses. In addition, the fusion protein was stable and
soluble enough for solution NMR measurements .1 week
at 258C.
Fig. 4. (a) Overlay of the
1H–
15N HSQC spectra of the FKBP12–FRB fusion protein in the absence (black) and presence (red) of FK506. (b) Chemical shift
differences between the FKBP12–FRB fusion protein in the presence and absence of FK506. (c) Overlay of the
1H–
15N HSQC spectra of the FKBP12–FRB
fusion protein in the absence (black) and presence (red) of rapamycin. (d) Chemical shift differences between the FKBP12–FRB fusion protein in the absence
and presence of rapamycin. (e) Overlay of the
1H–
15N HSQC spectra of the FKBP18–FRB fusion protein in the absence (black) and presence (red) of
rapamycin. (f) Chemical shift differences between the FKBP38–FRB fusion protein in the absence and presence of rapamycin.
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814Fig. 5. (a) Overlay of the
1H–
15N HSQC spectra of isolated FKBP12 (black) and the FKBP12–FRB fusion protein (red). (b) Chemical shift differences of
FKBP12 residues between isolated FKBP12 and the FKBP12–FRB fusion protein. (c) Overlay of the
1H–
15N HSQC spectra of isolated FKBP12 (black) and
the FKBP12–FRB fusion protein (red) in the presence of rapamycin. (d) Chemical shift difference of the FKBP12 residues between the isolated FKBP12 and
FKBP12–FRB fusion protein in the presence of rapamycin. (e) The FKBP12 residues shifted upon fusion with FRB domain in the presence of rapamycin were
mapped on the crystal structure (1NSG) of the FKBP12–FRB2rapamycin ternary complex. Red represents chemical shift differences .0.3 p.p.m., orange of
0.2 and yellow of 0.1 p.p.m. Black represents Pro or missing residues. FKBP12 was shown in ribbon, FRB in surface and rapamycin in stick. FRB residues in
contact with FKBP12 in the crystal structure of the FKBP12–FRB2rapamycin ternary complex (Liang et al., 1999) were colored cyan. (f) Open-book
representation of (e).
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We carried out DSC measurements for FKBP12 and the
FKBP12–FRB fusion protein in the absence and presence of
two inhibitors, FK506 and rapamycin. The DSC curve of
FKBP12 in the ligand-free state exhibited a single peak
(black) with a transition midpoint (TM) of 65.8 (+0.1)8C.
On addition of FK506 (blue) or rapamycin (red), the TM was
shifted to 77.6 (+0.4)8C or 76.5 (+0.4)8C, respectively,
demonstrating the thermodynamic stabilization of the
FKBP12 via the drug association (Fig. 3a). DSC analysis of
the FKBP12–FRB fusion protein exhibited two separated
peaks (TM of 43.8 (+0.4) and 49.6 (+0.1)8C) in the ligand-
free state (black) (Fig. 3b). This revealed that the two protein
moieties, FKBP12 and FRB, were independent or only
weakly interacting in the ligand-free state. The FKBP12
moiety of the FKBP12–FRB fusion protein was less stable
than the isolated FKBP12 domain in the DSC analysis.
Destabilization effect by fusion with labile protein was
reported for other protein systems (Blondel et al., 1996;
Novokhatny and Ingham, 1997; Auton et al., 2010), and was
assumed to be general.
On addition of FK506, one of the peaks was shifted to a
higher temperature (TM from 49.6 (+0.1) to 70.58C
(+0.2)), while the other did not change (blue) (TM from
43.8 (+0.4) to 43.9 (+0.2)8C) (Fig. 3b). Since FK506 is
known to bind to FKBP12, but not to FRB, the shifted DSC
peak could be assigned to the FKBP12 moiety. Finally, the
DSC curve of the FKBP12–FRB fusion protein exhibited a
single peak (red) with a TM of 74.9 (+0.3)8C (Fig. 3b) in
the presence of rapamycin. This indicated that a ternary
complex was formed among the FKBP12 moiety, rapamycin
and the FRB moiety, which is consistent with a previous
report (Laura et al., 2005). Thus, DSC measurements
deﬁnitely identify the ligand association in the fusion
protein.
NMR spectroscopy
Next, we used an NMR spectroscopy to monitor the associ-
ation of rapamycin or FK506 to the FKBP12 protein or
FKBP12–FRB fusion protein at the residue level. In
FKBP12, 97% of the resonance assignments of the main
chain atoms were established without or with rapamycin. In
the fusion protein, resonance assignments for 79% of the
main-chain atoms were obtained for the ligand-free state,
79% for the FK506-bound state and 80% for the rapamycin-
bound state, respectively. Figure 4a shows an overlay of the
1H–
15N HSQC spectra of the FKBP12–FRB fusion protein
without ligand binding and with FK506. Figure 4b shows the
amide group chemical shift difference in the FKBP12–FRB
fusion protein between the ligand free and FK506-bound
forms. Marked chemical shift changes were observed in the
FKBP12 moiety, but only negligible chemical shift changes
were observed in the FRB moiety. Residues with large
chemical shift changes were mostly located in the previously
reported FK506 binding surface (Kissinger et al., 1995).
However, the addition of rapamycin to the FKBP12–FRB
fusion protein caused marked chemical shift changes among
the residues of both the FKBP12 and FRB moieties (Fig. 4c
and d), particularly from R18 to S39 and F46 to M66 in the
FKBP12 moiety, and I2021 to E2052 and D2102 to V2106
in the FRB moiety. These residues were shown to be located
in the interface in the ternary complex (Choi et al., 1996;
Liang et al., 1999). Thus, NMR could clearly distinguish two
different drug-binding modes. Next, we searched for drug
candidates that associate with the FRB moiety but not with
the FKBP12 moiety. We replaced the FKBP12 moiety with
the PPI domain of FKBP38, which does not associate with
FK506 or rapamycin. The FKBP38 PPI domain-FRB fusion
protein (denoted as FKBP38–FRB) was also soluble and
stable, and to this fusion protein we added rapamycin and
recorded the NMR spectra. The residues with large chemical
Fig. 6. (a) Overlay of the
1H–
15N HSQC spectra of the isolated FKBP38 PPI domain (black) and FKBP38–FRB fusion protein (red). (b) Chemical shift
differences of FKBP12 residues between isolated FKBP38 PPI domain and the FKBP38–FRB fusion protein.
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FRB moiety but not to the FKBP38 moiety (Fig. 4e and f).
Thus, the FKBP38–FRB fusion protein is useful for the
screening of drugs that bind only to the FRB moiety.
NMR analysis and comparison of the FKBP12–FRB and
FKBP38–FRB fusion proteins with the isolated FKBPs
Figure 5a shows an overlay of the
1H–
15N HSQC spectra of
FKBP12 and the FKBP12–FRB fusion protein. Chemical
shift difference was small except for T21 and the C-terminal
residues. C-terminus and T21 exhibited chemical shift differ-
ence of 0.2 p.p.m. (Fig. 5b). Since FRB was fused to the
C-terminus of FKBP12 via the 13 residue linker, the chemi-
cal shift change of the C-terminal residue was caused by
fusion artifact. In the 3D structure of FKBP12, T21 was
located close to the C-terminus so that, it is assumed that the
chemical shift difference of T21 is also caused by fusion
artifact. Thus, we concluded that the FKBP12 and FRB moi-
eties in the fusion protein are independent with each other.
Figure 5c shows the overlay of the HSQC spectra of
FKBP12 and the FKBP12–FRB fusion protein complexed
with rapamycin. Large chemical shift difference was
observed around R42 to E61 and A81 to T96 (Fig. 5d). They
were mapped on the crystal structure of the FKBP12–
FRB2rapamycin ternary complex (Choi et al., 1996; Liang
et al., 1999). F46 to M49 of the helix region, L50 to I56 and
A81 to T96 loop regions were located in the interface
between FKBP12 and FRB (Fig. 5e and f). Previous NMR
analysis revealed that afﬁnity of FRB for rapamycin was
2000-fold enhanced by association of the drug with
FKBP12 (Laura et al., 2005) by protein–protein interaction.
Our data support their observation. Moreover, extensive
protein–protein interaction in the FKBP12–FRB-rapamycin
ternary complex was also supported by our DSC analysis
that only single peak was observed for the FKBP12–FRB
fusion protein in the presence of rapamycin.
Next, we compared
1H–
15N HSQC spectra of the isolated
FKBP38 PPI domain and FKBP38–FRB fusion protein in
the absence of rapamycin (Fig. 6a and b). NMR spectra of
FKBP38 moiety was superimposed well with the isolated
FKBP38 PPI domain. This indicates that the inter-protein
interaction was negligible in the fusion protein. This is
similar to the generally used solubility enhancement tag
(denoted as SET), such as GB1 (Zhou et al., 2001; Zhou and
Wagner, 2010), while it remains poorly understood how the
SET enhances the solubility of fused proteins. This was also
unclear from our experiment using FKBP12–FRB and
FKBP38–FRB fusion proteins, and further analysis will be
required to understand the stability and solubility enhance-
ment mechanism by protein fusion.
Conclusion
In the present paper, we showed that the stability and
solubility of the mTOR FRB domain could be improved by
the attachment of FKBP12 or FKBP38. This enabled the
application of this fusion protein to biophysical analysis.
We demonstrated that DSC detected ligand association at
the domain level, and NMR provided information on
protein–ligand interactions at the residue level. The present
method will be useful not only in the search for
FKBP12-dependent or -independent inhibitors of the mTOR
FRB domain but also as a general tool to assess protein–
ligand interactions.
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